The company strategy is to develop the project through the lead optimization stage and to take the development of one of its compounds at least as far as to the preclinical demonstration of proof-of-principle for the treatment of early Alzheimer's disease. Further development can be done by a strategic partnership with a company searching for new opportunities within the field of CNS or offering a M&A transaction.